Hosted on MSN59m
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback